Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate-Reference-Cited by-同舟云学术

Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate

Published:2020-10 Issue:04 Volume:10 Page:e390-e394
ISSN:2157-6998
Container-title:American Journal of Perinatology Reports
language:en
Short-container-title:AJP Rep

Author:

Cabrera Trevor B.¹,Speer Allison L.²,Greives Matthew R.³,Goff Donna A.⁴,Menon Neethu M.⁵,Reynolds Eric W.⁶

Affiliation:

1. Department of Pediatrics, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

2. Department of Pediatric Surgery, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

3. Department of Pediatric Plastic Surgery, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

4. Department of Pediatric Cardiology, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

5. Department of Pediatric Hematology, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

6. Department of Neonatal/Perinatal Medicine, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas

Abstract

AbstractWe present a case of a neonate born with kaposiform hemangioendothelioma (KHE), complicated by Kasabach-Merritt phenomenon (KMP) and other serious conditions, who was successfully treated with sirolimus. In addition to complications from thrombocytopenia and fluid overload, during the course of therapy, our patient experienced supratherapeutic drug levels at the commonly accepted starting dose of sirolimus. Patients with KHE and KMP should be closely monitored for potential complications of both the initial disease and unexpected side effects of treatments.

Publisher

Georg Thieme Verlag KG

Subject

Obstetrics and Gynaecology,Pediatrics, Perinatology, and Child Health

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1718901.pdf

Reference30 articles.

1. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis;L R Zukerberg;Am J Surg Pathol,1993

2. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals;S E Croteau;J Pediatr,2013

3. 2014 revised classification of vascular lesions from the International Society for the Study of Vascular Anomalies: radiologic-pathologic update;A C Merrow;Radiographics,2016

4. Kaposiform hemangioendothelioma presenting antenatally with a pericardial effusion;M A Walsh;J Pediatr Hematol Oncol,2008

5. Kasabach-Merritt syndrome;M el-Dessouky;J Pediatr Surg,1988

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Euphorbia helioscopia L. exhibits promising therapeutic effects on hemangioendothelioma and melanoma through angiogenesis inhibition;Phytomedicine;2024-07

2. Sirolimus monotherapy for Kasabach–Merritt phenomenon in a neonate; Case report;International Journal of Surgery Case Reports;2024-04

3. Sirolimus for vascular anomalies in the first year of life: a systematic review;Journal of Perinatology;2024-01-20

4. Kaposiform hemangioendothelioma presented with raynaud phenomenon: a case report;BMC Pediatrics;2023-11-17

5. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach–Merritt phenomenon in infants, a retrospective study;Annals of Medicine;2023-04-10